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RECOMBINANT HIRUDIN AS A NEW ANTICOAGULANT DURING CARDIAC OPERATIONS 
INSTEAD OF HEPARIN: SUCCESSFUL FOR AORTIC VALVE REPLACEMENT IN MAN 
Friedrich-Christian Riess, MD, a Christine L6wer, MD, a Christoph Seelig, MS, b Niels Bleese, MD, a 
Joachim Kormann, MD, a Gert Mtiller-Berghaus, MD, b and Bernd P6tzsch, MD, b 
Hamburg and Bad Nauheim, Germany 
Natural hirudin was isolated from the medicinal leech 
in the 1950s and characterized as a potent and specific 
thrombin inhibitor. Ever since recombinant hirudin (r- 
hirudin) was produced in sufficient quantities, the efficacy 
of this cofactor-independent anticoagulant has been 
shown in several studies and clinical investigations. 1 Re- 
cent experiments in the dog and pig model have demon- 
strated that r-hirudin is a safe and efficient anticoagulant 
for cardiac operations in which cardiopulmonary b pass 
(CPB) is used. 2' 3 Furthermore, r-hirudin has already been 
effectively used as an anticoagulant during CPB in a patient 
with chronic pulmonary embolism. 4 As a result of the 
positive results gained from previous animal and clinical 
studies, the Behringwerke, Marburg, Germany, is conduct- 
ing an investigation i  which patients with a heparin-induced 
thrombocytopenia m y be treated with r-hirudin. We report 
about one patient involved in this study, in whom r-hirudin 
was used as an anticoagulant during CPB. 
A 72-year-old woman weighing 52 kg was admitted after 
cardiac decompensation resulting from valvular aortic 
stenosis (A pressure 71 mm Hg, aortic valve opening area 
0.4 cm2). Left ventricular function was compromised 
(ejection fraction 37%) and pulmonary vascular resistance 
was increased to 296 dyne. sec. cm 5. After the diag- 
nostic cardiac atheterization, while the standard heparin 
anticoagulation regimen was still being administered. 
deep pelvic vein thrombosis developed along with a 
decrease in platelet count from 343,000 to 14,000 • 109/L. 
The suspected heparin-induced thrombocytopenia type II 
was confirmed by means of the heparin-induced platelet 
activation test. The only anticoagulant suitable for use 
during extracorporeal circulation proved to be r-llirudin 
HBW 023 (Behringwerke, Marburg, Germany), because 
all heparins and heparinoids caused platelet aggregation. 
The patient was transferred to our department for aortic 
valve replacement with r-hirudin used as the anticoagu- 
lant instead of heparin during CPB. 
Anticoagulation with phenprocoumon (Marcumar) be- 
cause of pelvic vein thrombosis was discontinued 3 days 
before the operation, and r-hirudin was simultaneously 
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substituted. An initial bolus of 0.2 mg/kg body weight was 
administered intravenously followed by an infusion regi- 
men with 0.1 mg/kg body weight per hour intravenously 
until the time of the operation to achieve a prolonged 
activated partial thromboplastin time (aPTI') within the 
range of 60 to 80 seconds. The resultant plasma concen- 
tration of r-hirudin was 1 to 1.5 /xg/ml. Anesthesia was 
maintained with intravenous infusions of propofol and 
pancuronium bromide along with intermittent doses of 
fentanyl (up to 25 ~g/kg body weight). The patient 
received a bolus of 9 nag of r-hirudin intravenously 10 
minutes before the start of CPB. The heart-lung machine 
contained a capillary membrane oxygcnator and was 
primed with 2000 ml of lactated Ringer's olution, 100 ml 
of mannitol solution (Osmofundin 15%), 50 ml of sodium 
bicarbonate, 750 ml of packed erythrocytes, and 5 mg of 
r-hirudin. The perfusion flow rate during normothermia 
was 3.9 L/min. The perfusion time was 83 minutes and the 
aortic crossclamp time, 60 minutes. Aortic valve replace- 
ment with a bioprosthesis was conducted with mild hypo- 
thermia up to 33 ~ C. To monitor the anticoagulation 
during CPB, we measured the ecarin clotting time (ECT) 5 
along with the aPTT in 10-minute intervals (Fig. 1). The 
aPTT was between 90 and 130 seconds and the ECT 
remained between 300 and 456 seconds. The plasma 
concentration of r-hirudin was kept within a range of 2.5 
to 3.2 /xg/ml throughout CPB. Four separate doses of 
r-hirudin (5, 5, 2.5, and 2.5 mg) were necessary to remain 
within this level. The half-life of r-hirudin depends on 
normal renal function. Therefore our patient showed a 
rapid fall of the r-hirudin concentration (documented by 
means of aPTT and ECT) toward the end of CPB. 
Throughout the CPB time the entire system remained free 
of clots. The pressure proximal to the oxygenator was 
constant during CPB. Bleeding and thromboembolic com- 
plications were not observed at any time during the 
operation or in the postoperative p riod. The total fluids 
from the chest drainage amounted to 240 ml. The entire 
postoperative course remained without sequel. 
Platelet function was measured by means of adenosine 
diphosphate-induced and collagen-induced platelet ag- 
gregation (Fig. 2). After the injection of r-hirudin the 
platelet function remained normal and then continued to 
diminish as a result of the CPB-mediated trauma. Within 
60 minutes after CPB the adenosine diphosphate-induced 
and collagen-induced platelet aggregations were 40% and 
60% Of the baseline values, respectively. At the end of the 
operation platelet function was almost fully restored. The 
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Fig. 1. Anticoagulation monitoring: Change of ECT (A) and aPPT (B) in correlation with r-hirudin 
plasma concentration before, during and after CPB. 
anticoagulation regimen with intravenous r-hirudin infu- 
sions (0.1 mg/kg body weight per hour) was continued for 
7 days during the postoperative period and led to aPTTs 
between 57 and 73 seconds. On the third postoperative 
day we again started simultaneous phenprocoumon (Mar~ 
cumar) therapy. The patient was able to be discharged in 
good health on the twelfth postoperative day. 
.' These data show that it is possible to perform cardiac 
operations in human beings with r-hirudin used as an 
anticoagulant for CPB without any problems. Further- 
more, ECT and aPTr  are suitable parameters to monito~ 
the plasma concentration and anticoagulation of r-him 
din. As a result of the intact kidney function and the shor 
half-life of r-hirudin, the plasma concentration decreasec 
rapidly at the end of CPB so that it was unnecessary t~
reverse any residual effects. In the case of an overdose ol 
during renal failure, it is possible to lower the r-hirudit 
plasma level quickly and effectively by means of hemofil 
tration. This was demonstrated in previous studies or 
nephrectomized pigs (unpublished ata) and during CP~ 
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Fig. 2. Platelet function: Platelet aggregation i duced by adenosine diphosphate (ADP) and by collagen 
before, during, and after CPB. Platelet counts were adjusted by dilution or centrifugation to 100,000 platelets 
/xl i and aggregation was induced by addition of adenosine diphosphate (10 mmol/L) or collagen (4/xg/ml). 
in human beings. 4 The stable platelet function as mani- 
fested by the low bleeding tendency is an especially good 
reason to surmise that r-hirudin is a better anticoagulant 
than heparin for CPB. 
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A NEW STAGED OPERATION FOR EXTENSIVE AORTIC ANEURYSM BY MEANS OF THE 
MODIFIED "ELEPHANT TRUNK" TECHNIQUE 
Kenji Kusuhara, MD, Shoichiro Shiraishi, MD, and Atsushi lwakura, MD, Hamamatsu, Japan 
A new first-stage operation through amedian sternotomy 
for extensive aortic aneurysm involving the ascending aorta, 
the aortic arch, and the descending aorta is presented. 
From the Division of Cardiovascular Surgery, Hamamatsu Rosai 
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Operative procedures. Minimum dissection of the as- 
cending aorta and the proximal aortic arch is done through 
a median sternotomy. Cardiopuimonary bypass is estab- 
lished by femoral and bicaval venous cannulations. The 
patient is cooled to a nasopharyngeal temperature of 18 ~ C. 
Then circulatory arrest is obtained with continuous retro- 
grade cerebral perfusion (CRCP)J Myocardial protection is
obtained by retrograde cardioplegia with crystalloid solution 
and blood. A longitudinal incision is made on the ascending 
aortic aneurysm and is extended minimally to the aortic arch. 
